DL2

Phase 2Biologic

Sun Pharma Advanced Research Company Limited

DL2 is one of 9 biologic programs targeting Locally Advanced Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Breast CancerActive, not recruiting

Locally Advanced Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Locally Advanced Breast Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

1 2

Taxol

Teva

Phase 2

1 3

Halaven

Eisai

Phase 2

1 4

Paraplatin

AAvyxa

Phase 2

1 5

BNT327 Optimized Dose

BioNTech

Phase 2

1 6

Nab-Placlitaxel

BioNTech

Phase 2

1 7

BNT327

BioNTech

Preclinical

1 8

DL2

Sun Pharma Advanced Research Company Limited

Phase 2

1 9

BNT323

BioNTech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Active, not recruiting

Locally Advanced Breast Cancer

NCT06449222

Q3 2030

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT07042100

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Recruiting· Sun Pharma Advanced Research Company Limited logo

Sun Pharma Advanced Research Company Limited·Phase 1·NCT07042100·177 enrolled

Locally Advanced Breast Cancer1 trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449222·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DL2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DL2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DL2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Pharma Advanced Research Company Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Sun Pharma Advanced Research Company Limited

DL2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2030

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Locally Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News